Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy.
about
Prognostic value of pretransplant FDG-PET in refractory/relapsed Hodgkin lymphoma treated with autologous stem cell transplantation: systematic review and meta-analysisClassical Hodgkin's lymphoma: the Lymphoma Study Association guidelines for relapsed and refractory adult patients eligible for transplantClinical experience of bendamustine in relapsed or refractory Hodgkin lymphoma: a retrospective analysis of the French compassionate use program in 28 patients.Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients.Relapsed Hodgkin lymphoma: management strategiesPrognostic factors and long-term outcome of autologous haematopoietic stem cell transplantation following a uniform-modified BEAM-conditioning regimen for patients with refractory or relapsed Hodgkin lymphoma: a single-center experience.Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group.Prognostic Value of FDG PET/CT before Allogeneic and Autologous Stem Cell Transplantation for Aggressive Lymphoma.Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine-based high-dose chemotherapy regimen.Simplified validated prognostic model for progression-free survival after autologous transplantation for hodgkin lymphoma.Surveillance imaging in pediatric Hodgkin Lymphoma.When should FDG-PET be used in the modern management of lymphoma?Recurrent Hodgkin lymphoma: toward a new definition of candidates for autologous stem cell transplant in the era of positron emission tomography scan and novel agents.Decision-making in the management of adult classical Hodgkin's lymphoma: determining the optimal treatment.Treatment of relapsed classical Hodgkin lymphoma in the brentuximab vedotin era.Current role of autologous and allogeneic stem cell transplantation for relapsed and refractory hodgkin lymphoma.The GHSG Approach to Treating Hodgkin's Lymphoma.New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma.Treatment of relapsed and refractory Hodgkin Lymphoma.Where Do the New Drugs Fit in for Relapsed/Refractory Hodgkin Lymphoma?Autologous stem cell transplantation for patients aged 60 years or older with refractory or relapsed classical Hodgkin's lymphoma: a retrospective analysis from the French Society of Bone Marrow Transplantation and Cell Therapies (SFGM-TC).Current strategies for salvage treatment for relapsed classical Hodgkin lymphoma.Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin's lymphoma.Autologous Stem Cell Transplantation After Second Line Brentuximab Vedotin in Relapsed or Refractory Hodgkin Lymphoma.Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma.Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma.Tandem autologous-haploidentical transplantation is a feasible and effective program for refractory Hodgkin lymphoma.PET/CT in the Evaluation of Relapsed or Refractory Hodgkin Lymphoma.Pre-transplant FDG-PET-based survival model in relapsed and refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and auto-SCT.Association of pre-transplantation positron emission tomography/computed tomography and outcome in mantle cell lymphoma.Pre-autologous transplantation PET/CT using Deauville criteria is an independent predictor of progression in relapsed refractory classical Hodgkin lymphoma.
P2860
Q26765151-2375DE98-E70B-4658-837D-D0E523B54AB0Q27022992-339D30AF-BB6A-420F-A1E5-E06325661F74Q33405891-97AA28FD-6AAB-4F73-A81C-885056507726Q36371623-9AE78055-3073-4FD3-A5D7-B9368F938844Q37008427-DDEBFD14-537C-4DC0-877D-1C91A3CBD226Q37126593-A4300190-6A8A-43CD-92CA-1F52F328FA01Q37216339-B78AD6FF-CE44-462C-A4C1-C5E451F03C6BQ37221563-B4D4B58D-766D-47C4-A6F7-66BF3ACC2567Q37316657-875E5835-1C0E-4EC4-A899-33CED03A5042Q37530611-2081F0AC-5FF5-4F52-91F8-9DBFE2EB6FD8Q38119890-E3959C61-B1CB-4093-825A-FF536BC92906Q38153086-F555B183-98B4-468F-A2E6-58FE280EC3DAQ38264356-FBC26B20-A42F-4105-BBA4-FF083CE11C1EQ38337152-8E8F2DBF-1963-4BA9-AF09-9C9A5562523FQ38361620-EC16C7E1-E53E-437A-A8C1-362B2D3F9F7FQ38368587-60438E88-36C4-4345-9E46-9965615E0EB3Q38506223-864646CA-A965-4503-894F-53283E521D13Q38896683-E99A91A8-8FF5-4453-83C0-FFC6D89175BFQ38920093-F11B89E5-D08E-41F0-8DB1-8DE5BD94AAF4Q39294879-FCAF494E-CF19-4517-8BF3-3A45CFEEFB47Q39865684-3E5584D6-922A-448E-9F0F-A8A46150FA4BQ42375641-77412DEB-C835-4FB9-B2F8-3EB29583C053Q45032304-A276E945-BD94-4861-B755-AE6E805DF0B4Q47562175-6EF6DB0A-2613-4F12-A5DD-94F7DA2D0951Q47563022-903A41EC-44C5-4958-99D2-5A1F1DAC1B7AQ47852690-B42077AF-51B9-458E-AC22-252CDFDE9E7AQ48362187-485BA6CD-BCFB-4F24-BD6A-78FDA6D54495Q49764261-41B77ECD-696A-46C6-8033-A3C4BC4D9641Q51236213-D4003E52-4E02-452E-8FC3-AC4FAD5C11E8Q53111697-8D39355D-8063-43F0-80E7-A42DDCE65C2AQ53775132-32DEEE94-9D98-464B-AEDD-133E12D5D971
P2860
Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Positron emission tomography r ...... ding to prior salvage therapy.
@ast
Positron emission tomography r ...... ding to prior salvage therapy.
@en
type
label
Positron emission tomography r ...... ding to prior salvage therapy.
@ast
Positron emission tomography r ...... ding to prior salvage therapy.
@en
prefLabel
Positron emission tomography r ...... ding to prior salvage therapy.
@ast
Positron emission tomography r ...... ding to prior salvage therapy.
@en
P2093
P2860
P1433
P1476
Positron emission tomography r ...... nding to prior salvage therapy
@en
P2093
Antonella Anastasia
Armando Santoro
Christian Chabannon
Diane Coso
Didier Blaise
Isabelle Brenot Rossi
Jean Marc Schiano
Monica Balzarotti
Raynier Devillier
Reda Bouabdallah
P2860
P304
P356
10.3324/HAEMATOL.2011.056051
P577
2012-01-22T00:00:00Z